Chia Tai Tianqing Pharmaceutical granted AstraZeneca exclusive ex-China rights to TQC3721, a new PDE3/4 inhibitor for chronic respiratory disease treatment, sending the Chinese drugmaker’s shares sharply higher.
verifying reliability
No specialized terms available for this topic.